Beamr video compression achieves up to 50% improvement for AVs
Investing.com -- Tempus AI (NASDAQ:TEM) stock fell 2.6% after the precision medicine technology company announced a proposed $400 million convertible senior notes offering due in 2030.
The Chicago-based company plans to use a portion of the proceeds to repay outstanding term loans, including immediately paying off its $275 million 2027 term loan. This move is expected to reduce interest expenses and enhance financial flexibility. Additional proceeds will fund capped call transactions to reduce potential dilution and for general corporate purposes.
The notes will be offered to qualified institutional buyers as general unsecured obligations of Tempus, with interest payable semiannually and maturity set for July 15, 2030. Upon conversion, Tempus may pay in cash, shares of its Class A common stock, or a combination of both, at its discretion.
Tempus also intends to grant initial purchasers an over-allotment option to buy up to an additional $60 million in notes within 13 days of the initial issuance.
In connection with the offering, the company plans to enter into privately negotiated capped call transactions with financial institutions. These transactions are designed to reduce potential dilution to Class A common stock upon conversion of the notes and/or offset cash payments exceeding the principal amount of converted notes.
The AI-powered precision medicine company expects the option counterparties to establish hedges through various derivative transactions and stock purchases around the time of pricing, which could affect the market price of both Tempus stock and the notes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.